Clinical Trial Detail

NCT ID NCT03502330
Title APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Yale University
Indications

melanoma

lung non-small cell carcinoma

renal cell carcinoma

Therapies

APX005M + Cabiralizumab + Nivolumab

APX005M + Cabiralizumab

Age Groups: adult senior

No variant requirements are available.